Group One Trading’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-124,900
Closed -$4.18M 8419
2026
Q1
$4.18M Buy
124,900
+97,400
+354% +$3.82M 0.01% 1440
2025
Q4
$1.27M Buy
27,500
+4,100
+18% +$225K ﹤0.01% 2683
2025
Q3
$1.58M Sell
23,400
-3,300
-12% -$245K ﹤0.01% 2551
2025
Q2
$2.24M Sell
26,700
-185,500
-87% -$13.9M ﹤0.01% 2033
2025
Q1
$15.2M Buy
212,200
+91,400
+76% +$4.45M 0.04% 422
2024
Q4
$5.43M Buy
120,800
+117,800
+3,927% +$6.1M 0.01% 1101
2024
Q3
$151K Buy
+3,000
New +$144K ﹤0.01% 3862
2023
Q1
Sell
-10,900
Closed -$21.6K 7904
2022
Q4
$21.6K Hold
10,900
﹤0.01% 5558
2022
Q3
$18K Buy
10,900
+10,173
+1,399% +$24.8K ﹤0.01% 6148
2022
Q2
$2K Sell
727
-73
-9% -$202 ﹤0.01% 7441
2022
Q1
$3K Sell
800
-2,353
-75% -$12.2K ﹤0.01% 7652
2021
Q4
$19K Sell
3,153
-454
-13% -$4.76K ﹤0.01% 7010
2021
Q3
$50K Sell
3,607
-440
-11% -$6.14K ﹤0.01% 6550
2021
Q2
$69K Sell
4,047
-1,440
-26% -$24.3K ﹤0.01% 6308
2021
Q1
$104K Buy
5,487
+5,440
+11,574% +$175K ﹤0.01% 5632
2020
Q4
$1K Sell
47
-2,260
-98% -$65.2K ﹤0.01% 6352
2020
Q3
$87K Buy
2,307
+1,987
+621% +$58.1K ﹤0.01% 4289
2020
Q2
$11K Buy
+320
New +$13.9K ﹤0.01% 5087

Group One Trading's SLNO Position: Q2 2026 in Review

Group One Trading sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 19,953 shares — an estimated $668K sold.

Group One Trading first reported a position in SLNO in Q3 2020 and held it in 19 quarters. The position peaked at $1.04M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Group One Trading reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 19,953 Soleno Therapeutics shares in Q2 2026, an estimated $668K.
  • Group One Trading first reported a position in Soleno Therapeutics in Q3 2020 and held it in 19 quarters.
  • Group One Trading's Soleno Therapeutics position peaked at $1.04M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.